EA201100268A1 - Вакцина - Google Patents

Вакцина

Info

Publication number
EA201100268A1
EA201100268A1 EA201100268A EA201100268A EA201100268A1 EA 201100268 A1 EA201100268 A1 EA 201100268A1 EA 201100268 A EA201100268 A EA 201100268A EA 201100268 A EA201100268 A EA 201100268A EA 201100268 A1 EA201100268 A1 EA 201100268A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen
vaccine
particle
delivery
combined
Prior art date
Application number
EA201100268A
Other languages
English (en)
Inventor
Ральф Леон Биман
Абделатиф Элуахаби
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201100268A1 publication Critical patent/EA201100268A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

В данном изобретении предлагается иммуногенная композиция, содержащая по меньшей мере одну частицу для доставки антигена и по меньшей мере один антиген, где антиген и частицу для доставки антигена соединяют, используя промежуточный линкер.
EA201100268A 2008-08-28 2009-08-26 Вакцина EA201100268A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9258208P 2008-08-28 2008-08-28
US9574708P 2008-10-15 2008-10-15
US16568809P 2009-04-01 2009-04-01
PCT/EP2009/060967 WO2010023216A1 (en) 2008-08-28 2009-08-26 Vaccine

Publications (1)

Publication Number Publication Date
EA201100268A1 true EA201100268A1 (ru) 2011-10-31

Family

ID=41338517

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100268A EA201100268A1 (ru) 2008-08-28 2009-08-26 Вакцина

Country Status (13)

Country Link
US (1) US8846080B2 (ru)
EP (1) EP2328613A1 (ru)
JP (2) JP5769624B2 (ru)
KR (1) KR20110050531A (ru)
CN (1) CN102202689A (ru)
AU (1) AU2009286769A1 (ru)
BR (1) BRPI0916884A2 (ru)
CA (1) CA2734950A1 (ru)
EA (1) EA201100268A1 (ru)
IL (1) IL211233A0 (ru)
MX (1) MX2011002267A (ru)
WO (1) WO2010023216A1 (ru)
ZA (1) ZA201101481B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031380T2 (en) * 2005-06-27 2017-07-28 Glaxosmithkline Biologicals Sa A method for producing vaccines
US9308253B2 (en) * 2011-09-19 2016-04-12 The Johns Hopkins University Cancer immunotherapy
DK3311827T3 (da) 2011-10-03 2023-04-03 Canqura Oncology Ab Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
GB201120000D0 (en) * 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
US9956276B2 (en) 2012-01-19 2018-05-01 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
AU2014292926B2 (en) 2013-07-25 2020-03-05 Exicure Operating Company Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
CA2932122C (en) * 2013-12-03 2022-04-19 Northwestern University Liposomal particles, methods of making same and uses thereof
PL3164113T3 (pl) 2014-06-04 2019-09-30 Exicure, Inc. Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych
CA2954279C (en) 2014-07-07 2023-11-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
WO2016007499A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
US9775898B2 (en) 2015-02-26 2017-10-03 Thevax Genetics Vaccine Co., Ltd. Vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific T-cell responses
WO2017057540A1 (ja) * 2015-09-30 2017-04-06 塩野義製薬株式会社 免疫賦活活性を有する核酸誘導体
US10940201B2 (en) 2015-09-30 2021-03-09 Shionogi & Co., Ltd. Nucleic acid derivative having immunostimulatory activity
CN108697779B (zh) 2016-01-07 2023-09-19 杜克大学 癌症疫苗和递送方法
WO2017200957A1 (en) * 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US10058606B2 (en) 2016-09-19 2018-08-28 Thevax Genetics Vaccine Co., Ltd. Hepatitis B therapeutic vaccines
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
SG11201908059YA (en) * 2017-03-29 2019-10-30 Shionogi & Co Nucleic acid derivative having immunostimulatory activity
MX2020000387A (es) 2017-07-13 2020-08-17 Univ Northwestern Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
CN111551729B (zh) * 2020-04-27 2021-02-09 浙江正熙生物技术股份有限公司 藻红蛋白免疫荧光探针制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2423335T3 (da) * 2001-06-21 2014-08-18 Dynavax Tech Corp Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
ES2295836T3 (es) * 2003-03-13 2008-04-16 Glaxosmithkline Biologicals S.A. Procedimiento de purificacion de citolisina bacteriana.
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
JP2007530449A (ja) * 2003-12-08 2007-11-01 イデラ ファーマシューティカルズ インコーポレイテッド 小オリゴヌクレオチドに基づく化合物による免疫刺激特性の調節
US20070129320A9 (en) * 2004-07-18 2007-06-07 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
JP2008524237A (ja) * 2004-12-17 2008-07-10 ダイナバックス テクノロジーズ コーポレイション 免疫寛容の誘導又は促進のための方法及び組成物
HUE031380T2 (en) * 2005-06-27 2017-07-28 Glaxosmithkline Biologicals Sa A method for producing vaccines

Also Published As

Publication number Publication date
JP2015163617A (ja) 2015-09-10
JP2012500827A (ja) 2012-01-12
BRPI0916884A2 (pt) 2016-06-14
CA2734950A1 (en) 2010-03-04
IL211233A0 (en) 2011-04-28
WO2010023216A1 (en) 2010-03-04
MX2011002267A (es) 2011-03-30
US8846080B2 (en) 2014-09-30
EP2328613A1 (en) 2011-06-08
CN102202689A (zh) 2011-09-28
AU2009286769A1 (en) 2010-03-04
US20110159081A1 (en) 2011-06-30
ZA201101481B (en) 2012-07-25
JP5769624B2 (ja) 2015-08-26
KR20110050531A (ko) 2011-05-13

Similar Documents

Publication Publication Date Title
EA201100268A1 (ru) Вакцина
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
CY1119183T1 (el) Πεπτιδια λυσοσωμiκης στοχευσης και χρησεις αυτων
CY1118761T1 (el) Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3)
EA201170227A1 (ru) Имидазолкарбоксамиды
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
UA103316C2 (ru) Вакцины на базе флавивирусов с дефектной репликацией и векторы для получения вакцин
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
EA201992456A2 (ru) Самостабилизирующиеся линкерные конъюгаты
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
IN2012DN02368A (ru)
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
FR2941231B1 (fr) Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques.
TN2010000213A1 (en) Wise binding antibodies and epitopes
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
GB201009273D0 (en) Novel vaccine
EA201401254A1 (ru) Самостабилизирующиеся линкерные конъюгаты
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa